📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. (2022)

First Author: Agache I

Attributed to: Cutaneous Immunology funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/all.15030

PubMed Identifier: 34324716

Publication URI: http://europepmc.org/abstract/MED/34324716

Type: Journal Article/Review

Volume: 77

Parent Publication: Allergy

Issue: 1

ISSN: 0105-4538